Artificial intelligence can help nonprofits
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Plea ends saga of Melchiori meltdown
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Dubroff: Central Coast technology hub makes a quantum leap
At the height of the dot-com bubble, the Central Coast made news because the Santa Barbara area had more domain name registrations per capita than any city in the nation. Twenty years later, there is talk about a new dot-com bubble and the Central Coast is in the news again. On Oct. 23, Google’s parent, Read More →
Deckers earnings beat analyst expectations
Goleta-based footwear and apparel company Deckers Brands reported an 8 percent increase in its second quarter revenue Oct. 24, beating analyst expectations with $2.71 in earnings per share. The company also announced the appointment of a new chairman to its board of directors, board member and former CFO of Coach Inc., Mike Devine. Former chairman Read More →
Amgen cuts list price of Repatha by 60 percent
Amgen doubled down on its decision to slash the list price of one of its newest drugs, Repatha, listing it for all patients at $5,840 per year. The Thousand Oaks-based biotech giant reduced the list price by 60 percent for some patients for the cholesterol medication a year before, and the announcement Oct. 24 discontinues Read More →
Amgen warns investors of ‘mini-tender’ offer
Biotech giant Amgen warned investors of a so-called “mini-tender” offer by TRC Capital Corp. that seeks to buy half a million of the company’s shares at below-market prices ahead of its third quarter earnings. The unsolicited offer is dated Oct. 11 and offers to purchase up to 500,000 of Amgen common stock at $192 per Read More →
Dubroff: Zuckerberg plays monopoly, dodges the truth
After watching Facebook chief executive Mark Zuckerberg labor to explain his company’s policies on privacy, diversity and currency in testimony before Congress on Oct. 23, I have come to some conclusions about the social media giant and its future. Like any company with monopoly or near-monopoly power, Facebook is way too concerned about costs. It Read More →
